Drug Profile
Fitusiran - Alnylam Pharmaceuticals/Sanofi
Alternative Names: ALN-AT3; ALN-AT3SC; SAR-439774Latest Information Update: 22 Mar 2024
Price :
$50
*
At a glance
- Originator Alnylam Pharmaceuticals
- Developer Alnylam Pharmaceuticals; Sanofi
- Class Antihaemorrhagics; Drug conjugates; Small interfering RNA
- Mechanism of Action Antithrombin III expression inhibitors; Haemostasis stimulants; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Haemophilia A; Haemophilia B
Most Recent Events
- 01 Mar 2024 Phase-I clinical trials in Haemophilia A (Treatment-experienced) in Taiwan (SC) (NCT06145373)
- 30 Oct 2023 Interim safety and efficacy data from the phase III ATLAS-OLE trial in haemophilia released by Sanofi
- 27 Oct 2023 Sanofi plans to submit regulatory applications to the US FDA for Haemophilia A and Haemophilia B in 2024